Sen, A., Khan, S., Rossetti, S., Broege, A., MacNeil, I., DeLaForest, A., . . . Laing, L. Assessments of prostate cancer cell functions highlight differences between a pan‐PI3K/mTOR inhibitor, gedatolisib, and single‐node inhibitors of the PI3K/AKT/mTOR pathway. Wiley.
Chicago Style (17th ed.) CitationSen, Adrish, et al. Assessments of Prostate Cancer Cell Functions Highlight Differences Between a Pan‐PI3K/mTOR Inhibitor, Gedatolisib, and Single‐node Inhibitors of the PI3K/AKT/mTOR Pathway. Wiley.
MLA (9th ed.) CitationSen, Adrish, et al. Assessments of Prostate Cancer Cell Functions Highlight Differences Between a Pan‐PI3K/mTOR Inhibitor, Gedatolisib, and Single‐node Inhibitors of the PI3K/AKT/mTOR Pathway. Wiley.
Warning: These citations may not always be 100% accurate.